US Stock MarketDetailed Quotes
AVD American Vanguard
- 6.130
- +0.250+4.25%
Close Sep 13 16:00 ET
- 6.130
- 0.0000.00%
Post 20:01 ET
176.76MMarket Cap-47153P/E (TTM)
6.150High5.960Low228.65KVolume5.980Open5.880Pre Close1.39MTurnover0.89%Turnover Ratio23.58P/E (Static)28.84MShares14.19452wk High0.50P/B156.80MFloat Cap4.95452wk Low0.12Dividend TTM25.58MShs Float34.987Historical High1.96%Div YieldTTM3.23%Amplitude0.473Historical Low6.088Avg Price1Lot Size
American Vanguard Stock Forum
Sign in to post a comment
$American Vanguard (AVD.US)$ I think this is a good opportunity
3
1
$Bitcoin (BTC.CC)$
Salim Ramji, the former head of $Blackrock (BLK.US)$ 's iShares and Index Investments, will take over as CEO of the asset management giant $American Vanguard (AVD.US)$ in July. This marks the first time in Vanguard's 50-year history that the company has appointed a CEO from outside the company. 🚀
Moreover, the new CEO, Ramji, is known for being "crypto-friendly." In contrast, Vanguard's previous stance was to stay far aw...
Salim Ramji, the former head of $Blackrock (BLK.US)$ 's iShares and Index Investments, will take over as CEO of the asset management giant $American Vanguard (AVD.US)$ in July. This marks the first time in Vanguard's 50-year history that the company has appointed a CEO from outside the company. 🚀
Moreover, the new CEO, Ramji, is known for being "crypto-friendly." In contrast, Vanguard's previous stance was to stay far aw...
13
Vanguard's decision to not offer bitcoin ETFs has frustrated some customers, leading to actions like Julian Fahrer, co-founder and CEO at Apollo, transferring his 401(k) from Vanguard to Fidelity. Analysts suggest institutions not offering bitcoin trading may see user outflows.
Vanguard's refusal to offer bitcoin ETFs, seen as unsafe, has irked some crypto enthusiasts. Despite some Wall Street brokerages' resistance, new funds' trading volume indicates strong market interest.
With earnings per share shrinking 26% annually over the last five years and dividend payments declining 1.5% yearly over the past decade, the company's stock is a less desirable dividend investment.
$2seventy bio (TSVT.US)$ analyst target price 8.2
$OptiNose (OPTN.US)$ all analysts target price 3
$Arcutis Biotherapeutics (ARQT.US)$ avg target price 9.6 (low 4, high 20)
Some of its chart show something good is going to happen, hope no more prank coming from these.
Vanguard and Blackrock also added position on September... ARQT has Vanguard only added position...
still have to wait FDA result though, nothing can be assured. the FDA tracker dot com only provide the...
$OptiNose (OPTN.US)$ all analysts target price 3
$Arcutis Biotherapeutics (ARQT.US)$ avg target price 9.6 (low 4, high 20)
Some of its chart show something good is going to happen, hope no more prank coming from these.
Vanguard and Blackrock also added position on September... ARQT has Vanguard only added position...
still have to wait FDA result though, nothing can be assured. the FDA tracker dot com only provide the...
1
4
The Invest for AmEx service charged a higher fee of 0.50% compared to other Vanguard services. The decision to discontinue implicates potential challenges that prevent the success of the service or failed to meet expectations.
Columns Expert Meeting Minutes | American Vanguard Corporation (AVD) Q4 2022 Earnings Call Transcript
Core points:
1. The 2022 strategic review by noting that we have also strengthened our balance sheet while returning significant value to our investors through increased dividends and share repurchases.
2. Our activities to invest to grow our business is a constant focus for the company. We focus on the development and full commercialization of our SIMPAS Ultimus technologies, for example, with the intro...
1. The 2022 strategic review by noting that we have also strengthened our balance sheet while returning significant value to our investors through increased dividends and share repurchases.
2. Our activities to invest to grow our business is a constant focus for the company. We focus on the development and full commercialization of our SIMPAS Ultimus technologies, for example, with the intro...
Gainers:
• $Checkmate Pharmaceuticals (CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics (AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer (SMCI.US)$ +14.3% (earnings report)
• $Plug Power (PLUG.US)$ +9.24% (t...
• $Checkmate Pharmaceuticals (CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics (AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer (SMCI.US)$ +14.3% (earnings report)
• $Plug Power (PLUG.US)$ +9.24% (t...
16
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Bob Ray : it's the lowest it has been since 2008